Radiation Therapy in Endometrial Carcinoma

Primary Treatment Context

The European Society of Gynaecological Oncology recommends surgery as the cornerstone of treatment, with total hysterectomy and bilateral salpingo-oophorectomy as the standard approach for most patients 2, 3
For medically inoperable patients with stage I/II disease, external beam radiotherapy and/or brachytherapy serves as definitive primary treatment, due to conditions such as obesity, cardiac morbidity, or diabetes 2, 3

The American College of Obstetricians and Gynecologists recommends no adjuvant therapy for low-risk disease (Stage IA, Grade 1-2, <50% myometrial invasion, LVSI negative), with a recurrence risk of approximately 10.4% 1
The National Comprehensive Cancer Network recommends vaginal brachytherapy as the preferred adjuvant treatment for intermediate-risk disease (Stage I, Grade 1-2, ≥50% myometrial invasion, LVSI negative), reducing vaginal/pelvic relapses without impacting overall survival 1, 2, 4, 5
For high-intermediate risk disease (Age ≥60 years with deeply invasive tumors OR Grade 3), patients with two of three major risk factors have locoregional relapse rates >15% and benefit from adjuvant pelvic radiotherapy 4, 5, 1
The American College of Radiology recommends adjuvant external beam radiotherapy with limited fields to increase locoregional control for high-risk disease (Stage I, Grade 3, ≥50% myometrial invasion) 4, 5, 1
Combined chemotherapy and radiotherapy is superior to radiotherapy alone, reducing the risk of relapse or death by 36% (HR 0.64, P=0.04) and improving cancer-specific survival (HR 0.55, P=0.01) for high-risk disease 6, 1

The European Society for Medical Oncology recommends combined chemotherapy and radiotherapy as the standard approach for optimally debulked Stage III-IV disease 6, 1
Chemotherapy alone (doxorubicin-cisplatin) significantly improves both progression-free survival (50% vs 38%, P=0.07) and overall survival (55% vs 42%, P=0.004) compared to whole abdominal radiation for advanced disease 6

The American Society for Radiation Oncology notes that randomized trials consistently demonstrate that adjuvant radiotherapy reduces locoregional recurrence but does NOT improve overall survival in early-stage disease, highlighting the importance of risk stratification 2

The National Cancer Institute recommends high-risk non-endometrioid cancers require more aggressive adjuvant therapy with combined chemotherapy and radiotherapy, due to significantly higher recurrence rates than endometrioid types 1

The American College of Radiology advises against overtreatment with external beam radiotherapy when vaginal brachytherapy would suffice for intermediate-risk disease, to avoid unnecessary gastrointestinal toxicity without survival benefit 1
The European Society for Medical Oncology recommends against using radiotherapy alone for high-risk Stage I or Stage III disease when combined chemoradiation is indicated, as this represents undertreatment with inferior outcomes 6, 1